Role and potential for therapeutic targeting of MYB in leukemia

Leukemia

Volumn 27, Issue 2, 2013, Pages 269-277

  Pattabiraman, D R ^a,b   Gonda, T J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN MYB; T LYMPHOCYTE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ALLELE; ALU SEQUENCE; APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; CELLS; CHROMOSOME TRANSLOCATION; ERYTHROLEUKEMIA; GENE LOCUS; GENE REPRESSION; HISTONE MODIFICATION; HUMAN; LEUKEMIA; LEUKEMOGENESIS; LYMPHATIC LEUKEMIA; MAST CELL LEUKEMIA; MOLECULAR PATHOLOGY; MYELOID LEUKEMIA; NONHUMAN; ONCOGENE MYB; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; RNA INTERFERENCE; STEM CELL; TRANSCRIPTION ELONGATION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA; PROTO-ONCOGENE PROTEINS C-MYB;

EID: 84873566930     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.225     Document Type: Review

References (122)

1. Beug H, von Kirchbach A, Doderlein G, Conscience JF, Graf T. Chicken hematopoietic cells transformed by seven strains of defective avian leukemia viruses display three distinct phenotypes of differentiation. Cell 1979; 18: 375-390.
2. Roussel M, Saule S, Lagrou C, Rommens C, Beug H, Graf T et al. Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation. Nature 1979; 281: 452-455.
3. Oh IH, Reddy EP. The myb gene family in cell growth, differentiation and apoptosis. Oncogene 1999; 18: 3017-3033.
4. Biedenkapp H, Borgmeyer U, Sippel AE, Klempnauer KH. Viral myb oncogene encodes a sequence-specific DNA-binding activity. Nature 1988; 335: 835-837.
5. Boyle WJ, Lipsick JS, Reddy EP, Baluda MA. Identification of the leukemogenic protein of avian myeloblastosis virus and of its normal cellular homologue. Proc Natl Acad Sci USA 1983; 80: 2834-2838.
6. Nomura T, Tanikawa J, Akimaru H, Kanei-Ishii C, Ichikawa-Iwata E, Khan MM et al. Oncogenic activation of c-Myb correlates with a loss of negative regulation by TIF1beta and Ski. J Biol Chem 2004; 279: 16715-16726.
7. Alm-Kristiansen AH, Saether T, Matre V, Gilfillan S, Dahle O, Gabrielsen OS. FLASH acts as a co-activator of the transcription factor c-Myb and localizes to active RNA polymerase II foci. Oncogene 2008; 27: 4644-4656.
8. Saether T, Berge T, Ledsaak M, Matre V, Alm-Kristiansen AH, Dahle O et al. The chromatin remodeling factor Mi-2alpha acts as a novel co-activator for human c-Myb. J Biol Chem 2007; 282: 13994-14005.
9. Dai P, Akimaru H, Tanaka Y, Hou DX, Yasukawa T, Kanei-Ishii C et al. CBP as a transcriptional coactivator of c-Myb. Genes Dev 1996; 10: 528-540.
10. Oelgeschlager M, Janknecht R, Krieg J, Schreek S, Luscher B. Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific transactivation and on the cooperativity with NF-M. EMBO J 1996; 15: 2771-2780.
11. Zhao H, Jin S, Gewirtz AM. The histone acetyltransferase TIP60 interacts with c-Myb and inactivates its transcriptional activity in human leukemia. J Biol Chem 2012; 287: 925-934.
12. Jin S, Zhao H, Yi Y, Nakata Y, Kalota A, Gewirtz AM. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest 2010; 120: 593-606.
13. Hu YL, Ramsay RG, Kanei-Ishii C, Ishii S, Gonda TJ. Transformation by carboxyldeleted Myb reflects increased transactivating capacity and disruption of a negative regulatory domain. Oncogene 1991; 6: 1549-1553.
14. Sakura H, Kanei-Ishii C, Nagase T, Nakagoshi H, Gonda TJ, Ishii S. Delineation of three functional domains of the transcriptional activator encoded by the c-myb protooncogene. Proc Natl Acad Sci USA 1989; 86: 5758-5762.
15. Gonda TJ, Buckmaster C, Ramsay RG. Activation of c-myb by carboxy-terminal truncation: relationship to transformation of murine haemopoietic cells in vitro. Embo J 1989; 8: 1777-1783.
16. Grasser FA, Graf T, Lipsick JS. Protein truncation is required for the activation of the c-myb proto-oncogene. Mol Cell Biol 1991; 11: 3987-3996.
17. Tavner FJ, Simpson R, Tashiro S, Favier D, Jenkins NA, Gilbert DJ et al. Molecular cloning reveals that the p160 Myb-binding protein is a novel, predominantly nucleolar protein which may play a role in transactivation by Myb. Mol Cell Biol 1998; 18: 989-1002.
18. Aziz N, Miglarese MR, Hendrickson RC, Shabanowitz J, Sturgill TW, Hunt DF et al. Modulation of c-Myb-induced transcription activation by a phosphorylation site near the negative regulatory domain. Proc Natl Acad Sci USA 1995; 92: 6429-6433.
19. Bies J, Wolff L. Oncogenic activation of c-Myb by carboxyl-terminal truncation leads to decreased proteolysis by the ubiquitin-26S proteasome pathway. Oncogene 1997; 14: 203-212.
20. Saether T, Pattabiraman DR, Alm-Kristiansen AH, Vogt-Kielland LT, Gonda TJ, Gabrielsen OS. A functional SUMO-interacting motif in the transactivation domain of c-Myb regulates its myeloid transforming ability. Oncogene 2011; 30: 212-222.
21. Dash AB, Orrico FC, Ness SA. The EVES motif mediates both intermolecular and intramolecular regulation of c-Myb. Genes Dev 1996; 10: 1858-1869.
22. Westin EH, Gallo RC, Arya SK, Eva A, Souza LM, Baluda MA et al. Differential expression of the amv gene in human hematopoietic cells. Proc Natl Acad Sci USA 1982; 79: 2194-2198.
23. Gonda TJ, Metcalf D. Expression of myb, myc and fos proto-oncogenes during the differentiation of a murine myeloid leukaemia. Nature 1984; 310: 249-251.
24. Guerin M, Sheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 1990; 5: 131-135.
25. Ramsay RG, Thompson MA, Hayman JA, Reid G, Gonda TJ, Whitehead RH. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ 1992; 3: 723-730.
26. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer 2008; 8: 523-534.
27. Gewirtz AM, Calabretta BA. c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 1988; 242: 1303-1306.
28. Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, Miller TA et al. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 1991; 65: 677-689.
29. Allen 3rd RD, Bender TP, Siu G. c-Myb is essential for early T cell development. Genes Dev 1999; 13: 1073-1078.
30. Pearson R, Weston K. c-Myb regulates the proliferation of immature thymocytes following beta-selection. Embo J 2000; 19: 6112-6120.
31. Sumner R, Crawford A, Mucenski M, Frampton J. Initiation of adult myelopoiesis can occur in the absence of c-Myb whereas subsequent development is strictly dependent on the transcription factor. Oncogene 2000; 19: 3335-3342.
32. Vegiopoulos A, Garcia P, Emambokus N, Frampton J. Coordination of erythropoiesis by the transcription factor c-Myb. Blood 2006; 107: 4703-4710.
33. Thomas MD, Kremer CS, Ravichandran KS, Rajewsky K, Bender TP. c-Myb is critical for B cell development and maintenance of follicular B cells. Immunity 2005; 23: 275-286.
34. Lieu YK, Reddy EP. Conditional c-myb knockout in adult hematopoietic stem cells leads to loss of self-renewal due to impaired proliferation and accelerated differentiation. Proc Natl Acad Sci USA 2009; 106: 21689-21694.
35. Sakamoto H, Dai G, Tsujino K, Hashimoto K, Huang X, Fujimoto T et al. Proper levels of c-Myb are discretely defined at distinct steps of hematopoietic cell development. Blood 2006; 108: 896-903.
36. Emambokus N, Vegiopoulos A, Harman B, Jenkinson E, Anderson G, Frampton J. Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb. Embo J 2003; 22: 4478-4488.
37. Carpinelli MR, Hilton DJ, Metcalf D, Antonchuk JL, Hyland CD, Mifsud SL et al. Suppressor screen in Mpl-/-mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proc Natl Acad Sci USA 2004; 101: 6553-6558.
38. Papathanasiou P, Tunningley R, Pattabiraman DR, Ye P, Gonda TJ, Whittle B et al. A recessive screen for genes regulating hematopoietic stem cells. Blood 2010; 116: 5849-5858.
39. Sandberg ML, Sutton SE, Pletcher MT, Wiltshire T, Tarantino LM, Hogenesch JB et al. c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell 2005; 8: 153-166.
40. Kasper LH, Boussouar F, Ney PA, Jackson CW, Rehg J, van Deursen JM et al. A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature 2002; 419: 738-743.
41. Kauppi M, Murphy JM, de Graaf CA, Hyland CD, Greig KT, Metcalf D et al. Point mutation in the gene encoding p300 suppresses thrombocytopenia in Mpl-/-mice. Blood 2008; 112: 3148-3153.
42. Moscovici C, Samarut J, Gazzolo L, Moscovici MG. Myeloid and erythroid neoplastic responses to avian defective leukemia viruses in chickens and in quail. Virology 1981; 113: 765-768.
43. Radke K, Beug H, Kornfeld S, Graf T. Transformation of both erythroid and myeloid cells by E26, an avian leukemia virus that contains the myb gene. Cell 1982; 31(Pt 2): 643-653.
44. Clarke MF, Kukowska-Latallo JF, Westin E, Smith M, Prochownik EV. Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation. Mol Cell Biol 1988; 8: 884-892.
45. Selvakumaran M, Liebermann DA, Hoffman-Liebermann B. Deregulated c-myb disrupts interleukin-6-or leukemia inhibitory factor-induced myeloid differentiation prior to c-myc: role in leukemogenesis. Mol Cell Biol 1992; 12: 2493-2500.
46. Mushinski JF, Potter M, Bauer SR, Reddy EP. DNA rearrangement and altered RNA expression of the c-myb oncogene in mouse plasmacytoid lymphosarcomas. Science 1983; 220: 795-798.
47. Shen-Ong GL, Morse 3rd HC, Potter M, Mushinski JF. Two modes of c-myb activation in virus-induced mouse myeloid tumors. Mol Cell Biol 1986; 6: 380-392.
48. Belli B, Wolff L, Nazarov V, Fan H. Proviral activation of the c-myb proto-oncogene is detectable in preleukemic mice infected neonatally with Moloney murine leukemia virus but not in resulting end stage T lymphomas. J Virol 1995; 69: 5138-5141.
49. Li J, Shen H, Himmel KL, Dupuy AJ, Largaespada DA, Nakamura T et al. Leukaemia disease genes: large-scale cloning and pathway predictions. Nat Genet 1999; 23: 348-353.
50. Kanei-Ishii C, MacMillan EM, Nomura T, Sarai A, Ramsay RG, Aimoto S et al. Transactivation and transformation by Myb are negatively regulated by a leucine-zipper structure. Proc Natl Acad Sci USA 1992; 89: 3088-3092.
51. Ibanez CE, Lipsick JS. Structural and functional domains of the myb oncogene: requirements for nuclear transport, myeloid transformation, and colony formation. J Virol 1988; 62: 1981-1988.
52. Ferrao P, Gonda TJ, Ashman LK. Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity. Blood 1997; 90: 4539-4552.
53. Gonda TJ, Ramsay RG, Johnson GR. Murine myeloid cell lines derived by in vitro infection with recombinant c-myb retroviruses express myb from rearranged vector proviruses. Embo J 1989; 8: 1767-1775.
54. Metz T, Graf T, Leutz A. Activation of cMGF expression is a critical step in avian myeloid leukemogenesis. Embo J 1991; 10: 837-844.
55. Barletta C, Pelicci PG, Kenyon LC, Smith SD, Dalla-Favera R. Relationship between the c-myb locus and the 6q-chromosomal aberration in leukemias and lymphomas. Science 1987; 235: 1064-1067.
56. Pelicci PG, Lanfrancone L, Brathwaite MD, Wolman SR, Dalla-Favera R. Amplification of the c-myb oncogene in a case of human acute myelogenous leukemia. Science 1984; 224: 1117-1121.
57. Tomita A, Watanabe T, Kosugi H, Ohashi H, Uchida T, Kinoshita T et al. Truncated c-Myb expression in the human leukemia cell line TK-6. Leukemia 1998; 12: 1422-1429.
58. Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, Dik WA et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 2007; 110: 1251-1261.
59. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 2007; 39: 593-595.
60. O'Neil J, Tchinda J, Gutierrez A, Moreau L, Maser RS, Wong KK et al. Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med 2007; 204: 3059-3066.
61. Murati A, Gervais C, Carbuccia N, Finetti P, Cervera N, Adelaide J et al. Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia 2009; 23: 85-94.
62. Belloni E, Shing D, Tapinassi C, Viale A, Mancuso P, Malazzi O et al. In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels. Leukemia 2011; 25: 733-736.
63. Quelen C, Lippert E, Struski S, Demur C, Soler G, Prade N et al. Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. Blood 2011; 117: 5719-5722.
64. Dash A, Gilliland DG. Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 49-64.
65. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002; 3: 179-198.
66. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002; 39(Suppl 3): 6-11.
67. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica 2009; 94: 984-993.
68. Anfossi G, Gewirtz AM, Calabretta B. An oligomer complementary to c-mybencoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl Acad Sci USA 1989; 86: 3379-3383.
69. Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D et al. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 1991; 88: 2351-2355.
70. Hess JL, Bittner CB, Zeisig DT, Bach C, Fuchs U, Borkhardt A et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood 2006; 108: 297-304.
71. Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 2012; 119: 388-398.
72. Somervaille TC, Matheny CJ, Spencer GJ, Iwasaki M, Rinn JL, Witten DM et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 2009; 4: 129-140.
73. Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated selfrenewal program as essential for leukemia maintenance. Genes Dev 2011; 25: 1628-1640.
74. Arai M, Dyson HJ, Wright PE. Leu628 of the KIX domain of CBP is a key residue for the interaction with the MLL transactivation domain. FEBS Lett 2010; 584: 4500-4504.
75. De Guzman RN, Goto NK, Dyson HJ, Wright PE. Structural basis for cooperative transcription factor binding to the CBP coactivator. J Mol Biol 2006; 355: 1005-1013.
76. Goto NK, Zor T, Martinez-Yamout M, Dyson HJ, Wright PE. Cooperativity in transcription factor binding to the coactivator CREB-binding protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain. J Biol Chem 2002; 277: 43168-43174.
77. Lidonnici MR, Corradini F, Waldron T, Bender TP, Calabretta B. Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis. Blood 2008; 111: 4771-4779.
78. Waldron T, De Dominici M, Soliera AR, Audia A, Iacobucci I, Lonetti A et al. c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells. Leukemia 2011; Sep: 30.
79. Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86: 1-14.
80. Zhao L, Glazov EA, Pattabiraman DR, Al-Owaidi F, Zhang P, Brown MA et al. Integrated genome-wide chromatin occupancy and expression analyses identify key myeloid pro-differentiation transcription factors repressed by Myb. Nucleic Acids Res 2011; 39: 4664-4679.
81. Pattabiraman DR, Sun J, Dowhan DH, Ishii S, Gonda TJ. Mutations in multiple domains of c-Myb disrupt interaction with CBP/p300 and abrogate myeloid transforming ability. Mol Cancer Res 2009; 7: 1477-1486.
82. Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1992; 89: 11823-11827.
83. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998; 92: 712-736.
84. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007; 59: 75-86.
85. Bender TP, Thompson CB, Kuehl WM. Differential expression of c-myb mRNA in murine B lymphomas by a block to transcription elongation. Science 1987; 237: 1473-1476.
86. Hugo H, Cures A, Suraweera N, Drabsch Y, Purcell D, Mantamadiotis T et al. Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer 2006; 45: 1143-1154.
87. Thompson MA, Flegg R, Westin EH, Ramsay RG. Microsatellite deletions in the c-myb transcriptional attenuator region associated with over-expression in colon tumour cell lines. Oncogene 1997; 14: 1715-1723.
88. Drabsch Y, Hugo H, Zhang R, Dowhan DH, Miao YR, Gewirtz AM et al. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. Proc Natl Acad Sci USA 2007; 104: 13762-13767.
89. Suhasini M, Pilz RB. Transcriptional elongation of c-myb is regulated by NF-kappaB (p50/RelB). Oncogene 1999; 18: 7360-7369.
90. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 2005; 65: 9047-9055.
91. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC et al. Direct inhibition of the NOTCH transcription factor complex. Nature 2009; 462: 182-188.
92. Mitra P, Pereira LA, Drabsch Y, Ramsay RG, Gonda TJ. Estrogen receptor-alpha recruits P-TEFb to overcome transcriptional pausing in intron 1 of the MYB gene. Nucleic Acids Res 2012; 40: 5988-6000.
93. Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 2005; 19: 523-534.
94. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-1073.
95. Zor T, De Guzman RN, Dyson HJ, Wright PE. Solution structure of the KIX domain of CBP bound to the transactivation domain of c-Myb. J Mol Biol 2004; 337: 521-534.
96. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010; 116: 5089-5102.
97. Mullard A. Protein-protein interaction inhibitors get into the groove. Nat Rev Drug Discov 2012; 11: 173-175.
98. Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T, Green DR. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci USA 2008; 105: 20327-20332.
99. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
100. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
101. Hoffman-LaRoche. A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms Bethesda, MD: ClinicalTrials.gov, 2011.
102. Hoffman-LaRoche. A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors Bethesda, MD: ClinicalTrials.gov, 2012.
103. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004; 305: 1466-1470.
104. Ness SA. Myb binding proteins: regulators and cohorts in transformation. Oncogene 1999; 18: 3039-3046.
105. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 2012; 8: 277-284.
106. Kumar A, Lee CM, Reddy EP. c-Myc is essential but not sufficient for c-Mybmediated block of granulocytic differentiation. J Biol Chem 2003; 278: 11480-11488.
107. Schmidt M, Nazarov V, Stevens L, Watson R, Wolff L. Regulation of the resident chromosomal copy of c-myc by c-Myb is involved in myeloid leukemogenesis. Mol Cell Biol 2000; 20: 1970-1981.
108. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
109. Bujnicki T, Wilczek C, Schomburg C, Feldmann F, Schlenke P, Muller-Tidow C et al. Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-I. Leukemia 2011; 26: 615-702.
110. Leverson JD, Koskinen PJ, Orrico FC, Rainio EM, Jalkanen KJ, Dash AB et al. Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol Cell 1998; 2: 417-425.
111. Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 2011; 118: 693-702.
112. Kitagawa K, Hiramatsu Y, Uchida C, Isobe T, Hattori T, Oda T et al. Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb. Oncogene 2009; 28: 2393-2405.
113. Zhou F, Zhang L, van Laar T, van Dam H, Ten Dijke P. GSK3beta inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb. Mol Biol Cell 2011; 22: 3533-3540.
114. Kitagawa K, Kotake Y, Hiramatsu Y, Liu N, Suzuki S, Nakamura S et al. GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms. Cell Div 2010; 5: 27.
115. Rosson D, Tereba A. Transcription of hematopoietic-associated oncogenes in childhood leukemia. Cancer Res 1983; 43: 3912-3918.
116. Ferrari S, Torelli U, Selleri L, Donelli A, Venturelli D, Narni F et al. Study of the levels of expression of two oncogenes, c-myc and c-myb, in acute and chronic leukemias of both lymphoid and myeloid lineage. Leuk Res 1985; 9: 833-842.
117. Ohyashiki K, Ohyashiki JH, Kinniburgh AJ, Toyama K, Ito H, Minowada J et al. myb oncogene in human hematopoietic neoplasia with 6q-anomaly. Cancer Genet Cytogenet 1988; 33: 83-92.
118. Siegert W, Beutler C, Langmach K, Keitel C, Schmidt CA. Differential expression of the oncoproteins c-myc and c-myb in human lymphoproliferative disorders. Eur J Cancer 1990; 26: 733-737.
119. Okada M, Tada M, Kanda N, Masuda M, Mizoguchi H, Kazuma M et al. c-myb gene analysis in T-cell malignancies with del(6q). Cancer Genet Cytogenet 1990; 48: 229-236.
120. Jacobs SM, Gorse KM, Kennedy SJ, Westin EH. Characterization of a rearrangement in the c-MYB promoter in the acute lymphoblastic leukemia cell line CCRF-CEM. Cancer Genet Cytogenet 1994; 75: 31-39.
121. Sinclair P, Harrison CJ, Jarosova M, Foroni L. Analysis of balanced rearrangements of chromosome 6 in acute leukemia: clustered breakpoints in q22-q23 and possible involvement of c-MYB in a new recurrent translocation, t(6;7)(q23;q32 through 36). Haematologica 2005; 90: 602-611.
122. Kawamata N, Zhang L, Ogawa S, Nannya Y, Dashti A, Lu D et al. Double minute chromosomes containing MYB gene and NUP214-ABL1 fusion gene in T-cell leukemia detected by single nucleotide polymorphism DNA microarray and fluorescence in situ hybridization. Leuk Res 2009; 33: 569-571.